VTN and Miyoshi myopathy: To test this hypothesis, we compared the abilities of the Fc domain of TE1146 and daratumumab in mediating antibody‐dependent cell‐mediated cytotoxicity (ADCC) and complement‐dependent cytotoxicity (CDC) against various MM cells by incubating them with serial dilutions of TE‐1146 or daratumumab in the presence of i) peripheral blood mononuclear cells (PBMCs) containing human immune cells to assess ADCC or ii) human plasma containing complement proteins to assess CDC.